沙库巴曲缬沙坦钠联合琥珀酸美托洛尔治疗慢性心力衰竭的临床效果及预后分析

Clinical Effect and Prognosis of Sacubitril Valsartan Sodium Combined with Metoprolol Succinate in the Treatment of Chronic Heart Failure

目的 分析沙库巴曲缬沙坦钠联合琥珀酸美托洛尔治疗慢性心力衰竭的临床效果及预后情况。方法 将我院2020年1月至2021年1月收治的96例慢性心力衰竭患者,随机分为观察组和对照组各48例。对照组采用琥珀酸美托洛尔治疗,观察组在对照组基础上采用沙库巴曲缬沙坦钠治疗,对比两组的临床疗效及预后情况。结果 治疗后,观察组的心功能指标、血清学指标均优于对照组(P <0.05)。观察组治疗总有效率高于对照组(P <0.05)。两组的不良反应发生率比较差异无统计学意义(P>0.05)。观察组6个月内复发率低于对照组(P <0.05)。结论 沙库巴曲缬沙坦钠联合琥珀酸美托洛尔治疗慢性心力衰竭的效果显著,能够有效改善患者的心功能指标和血清学指标,降低疾病复发率,预后较好。

Objective To analyze the clinical effecty and prognosis of sacubitril valsartan sodium combined with metoprolol succinate in the treatment of chronic heart failure.Methods 96 patients with chronic heart failure admitted to our hospital from January 2020to January 2021 were randomly divided into observation group and control group,with 48 cases in each group.The control group was treated with metoprolol succinate,and the observation group was treated with sacubatrovalsartan sodium on the basis of the control group.The clinical efficacy and prognosis of the two groups were compared.Results After treatment,the cardiac function indicators and serological indicators of the observation group were better than those of the control group(P 0.05).Conclusions Sacubitril valsartan sodium combined with metoprolol succinate has significant effect in the treatment of chronic heart failure,which can effectively improve the cardiac function indicators and serological indicators,and reduce the disease recurrence rate,with better prognosis.